<DOC>
	<DOC>NCT00758251</DOC>
	<brief_summary>The purpose of this study is to assess severity of illness in schizophrenia patients in routine clinical practice at the time of entry in the study and after the treatment with Seroquel XR for 8 weeks. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.</brief_summary>
	<brief_title>Observation of Change in Clinical Global Impression Scores in Schizophrenia Patients Receiving Seroquel XR Treatment</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Adult patients with Schizophrenia prescribed on Seroquel XR according to the approved product information before inclusion in this noninterventional study Signed and dated Patient Informed Consent (ICF) Hypersensitivity to the active substance or to any of the excipients of Seroquel XR</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Seroquel XR</keyword>
	<keyword>CGI</keyword>
</DOC>